Table 5.

External validation with our hospital data.

Research variables	28-day mortality			90-day mortality
	HR	95% CI	P-value	HR	95% CI	P-value
Model 1
FFP transfusion vs. non-FFP transfusion	3.572	1.956–6.524	<0.001	2.758	1.690–4.500	<0.001
Model 2
FFP transfusion vs. non-FFP transfusion	2.470	1.272–4.795	0.008	1.979	1.142–3.429	0.015
Model 3
FFP transfusion vs. non-FFP transfusion	2.493	1.273–4.884	0.008	2.386	1.363–4.175	0.002
Sensitivity analysis with different coagulation indexes
Non-hypocoagulable group (INR ≤ 1.20)*	1.313	0.175–9.856	0.791	0.793	0.172–3.658	0.767
Hypocoagulable group (INR > 1.20)*	1.931	0.905–4.119	0.089	1.608	0.853–3.030	0.142
Non-hypocoagulable group (PTT ≤ 40)*	2.775	0.617–12.472	0.183	2.748	0.805–9.379	0.107
Hypocoagulable group (PTT > 40)*	2.426	1.133–5.193	0.023	1.814	0.974–3.379	0.061
Subgroup analysis in FFP transfusion group (N = 174)
Low transfusion volume vs. high transfusion volume*#	1.884	1.040–3.4146	0.037	1.882	1.096–3.232	0.022

The significant P-value was indicated in bold.

^*Adjusting for the covariates of Model 2.

^#Median as cutoff value. CI, confidence interval; FFP, fresh frozen plasma; HR, hazard ratio; INR, international normalized ratio; and PTT, partial thromboplastin time.